Safety of a new drug for sickle cell pain
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new medicine called anumigilimab to see if it is safe for people with sickle cell disease. The study focuses on those who have had pain crises recently, to help manage and prevent them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have sickle cell disease of any type.
- You must have had 1 to 12 pain crises in the past 12 months that required a visit to a medical facility and pain medication.
- You must be on a stable dose of hydroxyurea (if you take it) for at least 30 days, or have stopped or refused it.
- You must not have a very low white blood cell count (below 2.5 x 10^9 cells per liter).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding acupuncture to standard pain treatments can help manage pain in people with sickle cell disease. It involves brain scans, questionnaires, and acupuncture sessions to see if this approach reduces pain and improves quality of life.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
This trial tests a new medicine (SIL-8301) to help control red blood cell breakdown (hemolysis) in people with sickle cell disease. It is for those who are already taking hydroxyurea and have had few pain crises but still have complications from hemolysis.
This trial compares different ways to manage sickle cell pain crises in the hospital, using a flexible 'platform' design to test combinations of pain medicines. It aims to find the safest and most effective approach to reduce pain and improve recovery.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.